Abstract 189P
Background
Tertiary lymphoid structures (TLSs) are lymphocyte aggregates that correlate with better prognosis in most cancers. TLSs possess anti-tumor potentials but their compositions and functions vary across cancer types and stages, so our understanding of TLS remains largely descriptive. Current studies are limited to fixed pathological samples for immunohistochemistry or spatial transcriptomics, yielding restricted mRNA content in rare cell types. To study the anti-tumor role of TLS, we choose prostate cancer, cause of one of the highest cancer-related deaths in U.S, as our disease model. Castration-resistant prostate cancer (CRPC) is a devastating disease state with high mortality and limited treatment options, including immune checkpoint therapy (ICT). Due to the positive correlation between TLS and ICT response, we want to promote the anti-tumor potentials of TLS in CRPC.
Methods
We aim to develop a region-specific in situ labeling methodology to capture live TLS cells in CRPC mice for characterizations. Since loss of PTEN is a common mutation in prostate cancer, we employed PB-Cre+;Ptenloxp/loxp mice to elucidate TLS composition and function in CRPC. Through photocatalytic labeling in tissue sections, we covalently tagged biotin to live TLS cells, followed by biotin+ TLS isolation for single-cell RNA sequencing (scRNA-seq) analysis.
Results
Our region-specific labeling method is validated in cell lines and tissue sections, including germinal center (GC) enrichment. Our study identified key clusters within CRPC TLS, including CD8+T, follicular helper T (Tfh), GC B, Mki67+ T/B cells and Naaa+ dendritic cells (DCs), among others. TLS also enriched for certain clones in TCR/BCR repertoires.
Conclusions
Through photocatalytic covalent labeling with biotin, we achieved image-guided labeling of live TLS cells for scRNA-seq and identified TLS-enriched cells with potential functions in antigen presentation, cytotoxicity and antibody secretion. We anticipate detecting changes in TLS signatures and functions following PI3K drug treatment, enabling a comprehensive analysis of TLS. Moreover, we plan to refine our methodology to expand the scope of application in other crucial biomedical research areas.
Legal entity responsible for the study
Peking University.
Funding
Peking University; Shenzhen Bay Laboratory.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
226P - Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment
Presenter: Manuel Cabeza Segura
Session: Poster Display session
Resources:
Abstract
228P - Modulating mitochondrial dynamics in TAMs to enhance anti-tumor immunity
Presenter: Pu-ste Liu
Session: Poster Display session
Resources:
Abstract
229P - Investigation of the effects of long-noncoding RNA NRAV on interferon response in melanoma
Presenter: Kadir Durmus
Session: Poster Display session
Resources:
Abstract
230P - Deciphering the mechanism of immunosuppressive activity of acetaminophen in the context of cancer immunotherapy
Presenter: Jeanne Lena
Session: Poster Display session
Resources:
Abstract
231P - The impact of calcitriol and tacalcitol on the Th17 lymphocytes in breast cancer
Presenter: Beata Filip-Psurska
Session: Poster Display session
Resources:
Abstract